Publications & Presentations

Filter by Category:

Results from the Phase 3 X-TOLE2 Study Evaluating Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults With Focal Onset Seizures (FOS)

Congress: 2026 Annual Meeting of the American Academy of Neurology (AAN) (April 19, 2026)
Authors: French, JA et al.

Tags

Azetukalner in Epilepsy

Treatment Experiences with Anti-seizure Medications (ASMs): Patient–Clinician Perspectives on Titration Burden, Quality of Life, and No‑Titration Options

Congress: 2026 Annual Meeting of the American Academy of Neurology (AAN) (April 19, 2026)
Authors: Stern, JM et al.

Tags

Azetukalner in Epilepsy

Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent KV7 Potassium Channel Opener, in Adults with Focal Epilepsy: ≥48-Month Interim Analysis of the Ongoing 7-Year X-TOLE Open-Label Extension

Congress: American Epilepsy Society Annual Meeting (December 8, 2025)
Authors: French, JA et al.

Tags

Azetukalner in Epilepsy

Multivariable Models Reporting Increased Economic and Humanistic Burden Among Patients With Epilepsy Reporting Focal Seizures (FS) Experiencing Moderate to Severe Depression Symptoms

Congress: American Epilepsy Society Annual Meeting (December 7, 2025)
Authors: Ong, A et al.

Tags

Epilepsy Real World Studies

Clinical Practice and Patient Burden Associated with Anti-Seizure Medication Titration: A Thematic Analysis

Congress: American Epilepsy Society Annual Meeting (December 7, 2025)
Authors: Stern, JM et al.

Tags

Epilepsy Real World Studies

Selective Potentiation of NaV1.1Channels by XPC-837 in Dravet Mice Suppresses Spontaneous Seizures, Prevents SUDEP and Increases LTP

Congress: American Epilepsy Society Annual Meeting (December 8, 2025)
Authors: Goodchild SJ, et al.

Tags

Early-Stage Programs

Depression Symptom Experience Among Patients with Epilepsy Reporting a Diagnosis of Focal Seizures (FS): A Patient-Reported Outcomes Study

Congress: American Epilepsy Society Annual Meeting (December 6, 2025)
Authors: Wagner, JM, et al

Tags

Epilepsy Real World Studies

Characterization of Long-Term Seizure Freedom in the Ongoing Open-Label Extension of X-TOLE: Potential Implications for Future Clinical Practice

Congress: American Epilepsy Society Annual Meeting (December 6, 2025)
Authors: Becker, D, et al.

Tags

Azetukalner in Epilepsy

Impact of Depression on Outcomes and Treatment Patterns in Patients with Newly Diagnosed Epilepsy: A Retrospective Claims Analysis

Congress: American Epilepsy Society Annual Meeting (December 6, 2025)
Authors: Terman S, et al.

Tags

Epilepsy Real World Studies

Azetukalner, a Novel, Potent Kv7 Channel Opener: Updates From the Ongoing Clinical Development Program in Major Depressive Disorder

Congress: Psych Congress (September 19, 2025)
Authors: Butterfield NM, et al.

Tags

Azetukalner in Depression

Selective Potentiation of NaV1.1 Channels by Small Molecule XPC-A in Dravet Mice Suppresses Spontaneous Seizures, Prevents SUDEP, and Increases Long Term Potentiation

Congress: 2025 International Epilepsy Congress (IEC) (August 30-September 3, 2025)
Authors: Goodchild SJ, et al.
Encore of AES 2024

Tags

Early-Stage Programs

Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent Kv7 Potassium Channel Opener in Adults With Focal Epilepsy: Update From the Ongoing 7-Year Open-Label Extension of X-TOLE

Congress: 2025 International Epilepsy Congress (IEC) (August 30-September 3, 2025)
Authors: French JA, et al.
Encore of AAN 2025

Tags

Azetukalner in Epilepsy

A Targeted Literature Review of Comorbidity Burden in Focal Onset Seizures

Congress: 2025 International Epilepsy Congress (IEC) (August 30-September 3, 2025)
Authors: Ong A, et al.
Encore of AES 2024

Tags

Azetukalner in Epilepsy

Azetukalner, a Novel Kv7 Potassium Channel Opener, in Adults with Major Depressive Disorder: A Randomized Clinical Trial

Source: JAMA Network Open
Authors: Butterfield NN et al.
Published online May 27, 2025

Tags

Azetukalner in Depression

Is the Mental Health Burden of Epilepsy Under-Recognized in Patients Reporting Focal Onset Seizures? A Patient-Reported Outcomes Study

Congress: 2025 Annual Meeting of the American Academy of Neurology (AAN) (April 5-9, 2025)
Authors: Wagner JM, et al.

Tags

Azetukalner in Epilepsy

Efficacy of Azetukalner in Focal Onset Seizure (FOS) Subtypes: Results From the Double-Blind, Placebo Controlled X-TOLE Study

Congress: 2025 Annual Meeting of the American Academy of Neurology (AAN) (April 5-9, 2025)
Authors: Perucca E, et al.

Tags

Azetukalner in Epilepsy

Interim analysis of the long-term efficacy and safety of azetukalner in an ongoing open-label extension study following a phase 2b clinical trial (X-TOLE) in adults with focal epilepsy

Source: Epilepsia Open
Authors: French JA, Porter RJ, Perucca E, Brodie MJ, Rogawski MA, Harden C, et al.
Published online March 7, 2025

Tags

Azetukalner in Epilepsy

Nav1.1 Potentiators Modulate Brain Rhythms Measured Through Quantitative Electrocorticography (qECoG) in a Dravet Mouse Model

Congress: 2024 Annual Meeting of the American Epilepsy Society (AES) (December 6-10, 2024)
Authors: Dube CM, et al.

Tags

Early-Stage Programs

Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial

Source: JAMA Neurology
Authors: French JA, Porter RJ, Perucca E, et al.
Published online October 09, 2023

Tags

Azetukalner in Epilepsy

Investors

Investor inquiries

Email alerts